Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Brief Summary

Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.

Website: https://clinicaltrials.gov/ct2/show/NCT02663518?term=NCT02663518&recrs=ab&draw=2&rank=1

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. 

Please refer to this study by its ClinicalTrials.gov identifier: NCT02663518

Contacts

Contact: Amani Ammari      amani@trilliumtherapeutics.com   

Contact: Kathleen Large      kathleen2@trilliumtherapeutics.com